2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Serologic Tests, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, Research, Translational Research, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3950 Efficacy and safety of DVP-lite, a reduced-intensity daratumumab-based regimen, in newly diagnosed AL amyloidosis with advanced cardiac disease or poor performance status: A prospective multicenter study

Tian Chen, Hongbin Yu2, Yu Wu, MD3
1 West China Hospital of Sichuan University, Chengdu, China
2 West China Hospital of Sichuan University, Chengdu, China
3 West China Hospital of Sichuan University, Chengdu, China

Background: Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd) is a standard first-line regimen with established efficacy in systemic light-chain (AL) amyloidosis. However, patients with advanced organ involvement or poor performance status may be unable to tolerate the toxicities associated with cyclophosphamide, full-intensity bortezomib, and dexamethasone. Given the substantial single-agent activity of daratumumab, we developed DVP-Lite, a reduced-intensity regimen that omits cyclophosphamide, reduces the dosing frequency of daratumumab during early treatment and the dose intensity of bortezomib, and replaces dexamethasone with methylprednisolone. We evaluated the efficacy and safety of DVP-Lite in this high-risk population.

Methods: In this prospective, multicenter study, 35 patients with biopsy-confirmed, newly diagnosed systemic AL amyloidosis were enrolled and treated with DVP-Lite. Daratumumab was administered subcutaneously at 1,800 mg every 2 weeks during cycles 1–6 and every 4 weeks thereafter through cycle 24. Bortezomib was administered at 1.3 mg/m² on the same schedule as daratumumab, together with methylprednisolone 40 mg. Eligibility required at least one of the following: European-modified Mayo 2004 stage III disease or an Eastern Cooperative Oncology Group performance status (ECOG PS) of 3–4. Baseline characteristics, organ involvement, treatment exposure, hematologic and organ responses, adverse events, and survival outcomes were prospectively collected. Hematologic and organ responses were assessed according to established consensus criteria, with the best response attained from DVP-Lite initiation until disease progression or initiation of subsequent therapy reported.

Results: A total of 35 patients were enrolled, with a median age of 69 years. Of these, 30 (85.7%) had an ECOG PS of 3–4, and 31 (88.6%) had European-modified Mayo 2004 stage III disease, including 18 (51.4%) with stage IIIb disease. Two patients were lost to follow-up before the first hematologic response assessment. The median duration of DVP-Lite treatment was 4.0 months (IQR, 3.0–9.5; range, 1–25 months). Among the 33 response-evaluable patients, the overall hematologic response rate was 81.8%, including very good partial response or better in 72.7% and complete response in 51.5%. Among responders, the median time to first hematologic response was 1.0 month. Among evaluable patients, the best cardiac and renal response rates were 51.5% (17/33) and 64.7% (11/17), respectively. Treatment-related adverse events occurred in 3 patients (8.6%) and included chills, vomiting, diarrhea, and blurred vision; all were grade 1–2. No grade ≥3 treatment-related adverse events and treatment-related discontinuations were observed. During follow-up, 7 deaths were confirmed: 3 from heart failure, 2 from infection, 1 from heart failure complicated by infection, and 1 from renal failure complicated by infection. All 4 deaths involving infection occurred during second-line therapy, including 3 in patients receiving BCMA-directed bispecific T-cell engagers and 1 in a patient receiving lenalidomide. None of the 7 deaths was considered attributable to DVP-Lite by the investigators. In a conservative landmark analysis that counted the 2 patients lost to follow-up within 1 month as deaths, mortality was 8.6% (3/35) at both 30 and 90 days.

Conclusions: DVP-Lite demonstrated rapid and deep hematologic responses and encouraging organ responses in patients with advanced cardiac disease or poor performance status, with no grade ≥3 treatment-related adverse events, treatment-related discontinuations, or treatment-related deaths observed. These findings support further evaluation of this reduced-intensity approach; longer follow-up and comparative studies are needed to establish response durability and long-term survival outcomes.

Tian Chen: No relevant conflicts of interest to declare.